Evidence map›Paper›PMID 41664821›Full record

ArticleNeuro-oncology advances

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts.

Rachael A Vaubel, Wenjuan Zhang, Nishika Karbhari, Ju-Hee Oh, Katie L Waller, Ann Mladek, Sonia Jain, Danielle M Burgenske, Paul A Decker, Matt L Kosel and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Rachael A VaubelDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Wenjuan ZhangDepartment of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Nishika KarbhariDepartment of Neuro-Oncology, Mayo Clinic, Rochester, MN, USA.
Ju-Hee OhDepartment of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Katie L WallerDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Ann MladekDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Sonia JainDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Danielle M BurgenskeDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Paul A DeckerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0002-3756-4227
Matt L KoselDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Zeng HuDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Lauren L OttDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Brett L CarlsonDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Katrina K BakkenDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Tugce PasaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Nicole R SarkariaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Surabhi TaleleDepartment of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Jeanette E Eckel-PassowDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0002-6113-1114
Patrizia SiniDepartment of Pharmacology and Translational Research, Boehringer Ingelheim, Vienna, Austria.
William F ElmquistDepartment of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0001-7489-4885

Funding

Therapy Evaluation CoreU19CA264362 · NCI · MAYO CLINIC ROCHESTER · PI PARNEY, IAN F · 2021 to 2025
$7.6M
Maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastomaR01CA285536 · NCI · MAYO CLINIC ROCHESTER · PI Jann N. Sarkaria · 2024 to 2026
$3.0M
NCI NIH HHS R01 CA285536NCI NIH HHS U19 CA264362
6 · The paper itself

Abstract

Background: Murine double minute 2 (MDM2) inhibitors reactivate wild-type p53 and are a promising therapy for glioblastoma, IDH-wildtype (GBM). Brigimadlin is a highly potent MDM2 inhibitor being tested in a phase 0/1 clinical trial in combination with radiation in GBM. Methods: Brigimadlin pharmacokinetics, pharmacodynamics, and efficacy were evaluated in GBM patient-derived xenografts (PDXs). Results: In vitro, brigimadlin impaired viability in Conclusions: Brigimadlin is highly effective in

Indexed as

brigimadlindrug deliveryglioblastomaMDM2p53

Identifiers

PMID41664821
PMCPMC12883205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.